(Q45868331)

English

Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels

scientific article published on 10 October 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

author name string

A D Shapiro

1

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

M V Ragni

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

R Kulkarni

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

J Oldenberg

4

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

A Srivastava

5

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

D V Quon

6

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

K J Pasi

7

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

H Hanabusa

8

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

I Pabinger

9

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

J Mahlangu

10

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

P Fogarty

11

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

D Lillicrap

12

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

S Kulke

13

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

J Potts

14

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

S Neelakantan

15

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

I Nestorov

16

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

S Li

17

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

J A Dumont

18

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

H Jiang

19

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

A Brennan

20

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

G F Pierce

21

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

publication date

10 October 2014

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

Journal of Thrombosis and Haemostasis

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

12

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

11

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

1788-1800

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

The hemophilias--from royal genes to gene therapy

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Improvements in factor concentrates

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Biological rationale for new drugs in the bleeding disorders pipeline

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Barriers to compliance with prophylaxis therapy in haemophilia

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

FcRn: the neonatal Fc receptor comes of age.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Population pharmacokinetics of recombinant factor VIII Fc fusion protein

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Likelihood based approaches to handling data below the quantification limit using NONMEM VI.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Clearance mechanisms of von Willebrand factor and factor VIII.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

von Willebrand disease and quantitative variation in von Willebrand factor

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Characterizing polymorphisms and allelic diversity of von Willebrand factor gene in the 1000 Genomes

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Up-regulation of platelet activation in hemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART).

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant fa

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Practice patterns in haemophilia A therapy -- global progress towards optimal care

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

An objective method for assessing adherence to prophylaxis in adults with severe haemophilia

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS).

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Costs of care in hemophilia and possible implications of health care reform

1 reference

https://api.crossref.org/works/10.1111%2FJTH.12723

21 January 2018

Identifiers

10.1111/JTH.12723

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25196897

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45868331&oldid=2087682883"